# EDGAR Filing Document

**Accession Number:** 0001060736
**File Stem:** 0001193125-23-010928
**Filing Date:** 2023-1
**Character Count:** 4446
**Document Hash:** 91e78ab9359da7d51f0cf77b2985be4f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-010928.hdr.sgml**: 20230119

**ACCESSION NUMBER**: 0001193125-23-010928

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230119

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230119

**DATE AS OF CHANGE**: 20230119

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Seagen Inc.
- **CENTRAL INDEX KEY:** 0001060736
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 911874389
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-32405
- **FILM NUMBER:** 23537344

**BUSINESS ADDRESS:**
- **STREET 1:** 21823 30TH DRIVE SE
- **STREET 2:** SUITE
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98021
- **BUSINESS PHONE:** 4255274000

**MAIL ADDRESS:**
- **STREET 1:** 21823 30TH DRIVE SE
- **STREET 2:** SUITE
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SEATTLE GENETICS INC /WA
- **DATE OF NAME CHANGE:** 20001116

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### Current Report

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 19, 2023

------

## Seagen Inc.

#### (Exact name of Registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-32405** | **91-1874389** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Commission**<br> **File Number)** | **(I.R.S Employer**<br> **Identification No.)** |

---

#### 21823 30th Drive SE

#### Bothell, Washington 98021

#### (Address of principal executive offices, including zip code)
(425) 527-4000

#### (Registrant's telephone number, including area code)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.001 | SGEN | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.**  |

---

On January 19, 2023, Seagen Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with *RAS* wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SEAGEN INC.** | **SEAGEN INC.** |
| Date: January 19, 2023 | By: | /s/ Jean I. Liu |
|  |  | Jean I. Liu |
|  |  | Chief Legal Officer |

---